CMA Explainer Maps Post-Approval Access Path for Canadians

What the CMA explainer says

The CMA notes that GLP-1 medications in Canada, including Ozempic and Wegovy, both contain semaglutide and are made by Novo Nordisk, but are approved for different uses [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. The association states that Ozempic is prescribed to help adults with type 2 diabetes control blood sugar, while Wegovy is approved for chronic weight management at a higher dose [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

The CMA also confirms that GLP-1 drugs can only be obtained with a prescription from a licensed health care provider, and that any website offering them without one is "a major red flag" [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

Provincial coverage remains uneven

According to the CMA, coverage rules still vary by province or territory. In Ontario, the Ontario Drug Benefit Program lists Ozempic as a Limited Use drug, meaning a doctor has to confirm it meets specific medical rules [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. In Alberta, the Alberta Drug Benefit List treats Ozempic as a step therapy/special authorization drug, with patients usually required to try other treatments first [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

Both programs only cover Ozempic for certain populations, like seniors, and public drug plans generally do not cover GLP-1 drugs for weight management [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. Obesity Canada has separately reported that fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications [Source: obesitycanada.ca/news/health-canada-generic-semaglutide-approval/].

Regulatory exclusivity and the generic pipeline

The CMA states that Novo Nordisk's regulatory exclusivity for semaglutide ended on January 4, 2026, in Canada, opening the door for generic versions [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. As of late December 2025, Health Canada had nine active applications from companies that want to sell generic semaglutide [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

Following the April 28 authorization of Dr. Reddy's Laboratories' generic semaglutide injection, Health Canada said it was reviewing eight other submissions for generic semaglutide by different companies and expects to make additional regulatory decisions in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The regulator added that many generic medicines in Canada are 45% to 90% cheaper than their brand-name counterparts [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Switching prescriptions and brand price differences

The CMA explainer indicates that patients will still need a prescription for a generic drug. In many cases, a prescriber can allow the pharmacy to switch a patient to a generic, and if insurance has already approved Ozempic, it will usually cover the generic automatically once available [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. Patients who choose to stay on the brand-name drug instead of the generic will usually be asked by most plans to pay the price difference out of pocket [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada].

Current pharmacy prices tracked on GLP1Prices.ca show Ozempic ranging from $215 to $663 CAD, and Wegovy ranging from $270 to $550 CAD. Patients can check insurance coverage details and follow the generic semaglutide tracker for ongoing pipeline updates. Other branded GLP-1 products on the Canadian market include Mounjaro, Zepbound, and Rybelsus.

Advertising caveats

The CMA notes that Canada has stricter rules around prescription drug advertising than some jurisdictions: companies can advertise the name of a prescription drug but cannot freely promote what a drug treats or promise results [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. The association also warns that influencer posts online do not follow the same rules as Canadian prescription drug ads, and points to Diabetes Canada warnings about misleading online ads that use fake logos from Diabetes Canada or Health Canada and claim endorsements that don't exist [Source: cma.ca/healthcare-for-real/can-you-get-glp-1-drugs-canada]. Visit our FAQ for additional context.